keyword
MENU ▼
Read by QxMD icon Read
search

sentinel lymph node, DCIS

keyword
https://www.readbyqxmd.com/read/29119692/impact-of-same-day-vs-day-before-pre-operative-lymphoscintigraphy-for-sentinel-lymph-node-biopsy-for-early-breast-cancer-local-australian-experience
#1
Yang Yang Huang, Amelie Maurel, Saud Hamza, Lee Jackson, Zeyad Al-Ogaili
INTRODUCTION: To assess the impact of delayed vs immediate pre-operative lymphoscintigraphy (LSG) for sentinel lymph node biopsy in a single Australian tertiary breast cancer centre. METHODS: Retrospective cohort study analysing patients with breast cancer or DCIS who underwent lumpectomy or mastectomy with pre-operative LSG and intra-operative sentinel lymph node biopsy from January 2015 to June 2016. RESULTS: A total of 182 LSG were performed...
November 9, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29096155/the-use-of-sentinel-lymph-node-biopsy-in-the-treatment-of-breast-ductal-carcinoma-in-situ-a-danish-population-based-study
#2
Emil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, Niels Kroman, Tove Filtenborg Tvedskov
OBJECTIVES: The risk of axillary metastases in breast cancer patients with only ductal carcinoma in situ (DCIS) is low. Thus, axillary staging with sentinel lymph node biopsy (SLNB) should only be used according to the current guidelines to avoid over-treatment and unnecessary morbidity. In the present study, the use of SLNB in patients with DCIS was evaluated nationally and compared across Danish departments. MATERIAL AND METHODS: A register-based study was conducted using the Danish Breast Cancer Group database...
October 27, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29024241/sentinel-node-biopsy-in-ductal-carcinoma-in-situ-of-the-breast-never-justified
#3
Luca Sorrentino, Alessandra Sartani, Daniela Bossi, Rosella Amadori, Manuela Nebuloni, Marta Truffi, Matteo Bonzini, Eliana Riggio, Diego Foschi, Fabio Corsi
Sentinel lymph node biopsy for ductal carcinoma in situ (DCIS) of the breast is not standard of care. However, nodal involvement for DCIS patients is reported. Aim of our study was to identify preoperative features predictive of nodal involvement in DCIS patients. We have retrospectively reviewed 175 patients with a preoperative diagnosis of DCIS following a vacuum-assisted breast biopsy, and undergoing surgery with sentinel node biopsy. Variables distribution was compared between patients upstaged to invasive cancer at final pathology and patients with a confirmed DCIS, and between positive vs negative sentinel node patients...
October 11, 2017: Breast Journal
https://www.readbyqxmd.com/read/29016707/minimal-clinical-impact-of-intraoperative-examination-of-sentinel-lymph-nodes-in-patients-with-ductal-carcinoma-in-situ-an-opportunity-for-improved-resource-utilization
#4
REVIEW
Eugene T Shin, Amy S Joehlin-Price, Doreen M Agnese, Debra L Zynger
Objectives: There is little information regarding sentinel lymph node (SLN) frozen-section examination in patients with a history of ductal carcinoma in situ (DCIS). We evaluated the usage, clinical impact, and pathology resources used for SLN cryosectioning in mastectomy cases with a DCIS history. Methods: Mastectomies with SLNs submitted from 2012 to 2013 at a tertiary care center were analyzed. Medicare reimbursement was used to estimate pathology health care expenditures of intraoperative frozen sections...
November 2, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28932627/addition-of-anti-estrogen-therapy-to-anti-her2-dendritic-cell-vaccination-improves-regional-nodal-immune-response-and-pathologic-complete-response-rate-in-patients-with-er-pos-her2-pos-early-breast-cancer
#5
Lea Lowenfeld, Salman Zaheer, Crystal Oechsle, Megan Fracol, Jashodeep Datta, Shuwen Xu, Elizabeth Fitzpatrick, Robert E Roses, Carla S Fisher, Elizabeth S McDonald, Paul J Zhang, Angela DeMichele, Rosemarie Mick, Gary K Koski, Brian J Czerniecki
HER2-directed therapies are less effective in patients with ER(pos) compared to ER(neg) breast cancer, possibly reflecting bidirectional activation between HER2 and estrogen signaling pathways. We investigated dual blockade using anti-HER2 vaccination and anti-estrogen therapy in HER2(pos)/ER(pos) early breast cancer patients. In pre-clinical studies of HER2(pos) breast cancer cell lines, ER(pos) cells were partially resistant to CD4(+) Th1 cytokine-induced metabolic suppression compared with ER(neg) cells...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28781782/-18-f-fluorodeoxyglucose-uptake-as-predictor-for-invasion-in-preoperatively-diagnosed-breast-ductal-carcinoma-in-situ-significance-in-cases-without-mass-formation
#6
Takaaki Fujii, Reina Yajima, Hironori Tatsuki, Hiroyuki Kuwano
A diagnosis of ductal carcinoma in situ (DCIS) at needle biopsy often changes to that of invasive ductal carcinoma as the definitive pathological diagnosis following the surgical procedure. The present study sought to identify the factors associated with invasive disease in cases diagnosed as DCIS on needle biopsy by analyzing (18)F-fluorodeoxyglucose-proton emission tomography (FDG-PET) findings. The present study retrospectively investigated the cases of 24 consecutive patients with primary breast cancer who were preoperatively diagnosed with DCIS by needle biopsy...
August 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28766201/selective-use-of-sentinel-lymph-node-surgery-in-patients-undergoing-prophylactic-mastectomy-using-intraoperative-pathology
#7
Brittany L Murphy, Amy E Glasgow, Gary L Keeney, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: Routine sentinel lymph node (SLN) surgery during prophylactic mastectomy (PM) is unnecessary, because most PMs do not contain cancer. Our institution utilizes intraoperative pathology to guide the surgical decision for resection of SLNs in PM. The purpose of this study was to review the effectiveness of this approach. METHODS: We identified all women aged ≥18 years who underwent bilateral PM (BPM) or contralateral PM (CPM) at our institution from January 2008 to July 2016...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28724885/invasive-ductal-carcinoma-within-a-benign-phyllodes-tumor
#8
Nancy Panko, Anwar A Jebran, Ameer Gomberawalla, Mark Connolly
BACKGROUND Phyllodes tumor (PT) is a rare neoplasm of the breast. Concomitant PT with invasive ductal carcinoma (IDC) is an even rarer occurrence. When ductal carcinoma in situ (DCIS) or IDC are detected within the specimen, the management changes from wide local excision to further staging work-up, including sentinel node biopsy and radiation. CASE REPORT We report the case of a 70-year-old presented with right breast mass whose pathology showed benign PT with concomitant IDC and DCIS. The patient elected for a wide excision of the mass with sentinel lymph node biopsy, which did not show any involvement...
July 20, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28335989/sentinel-lymph-node-biopsy-in-low-risk-settings
#9
Marios Konstantinos Tasoulis, Tyler Hughes, Gildy Babiera, Anees B Chagpar
BACKGROUND: Sentinel lymph node biopsy (SLNB) should be performed in patients with ductal carcinoma in situ (DCIS) undergoing mastectomy. Yet, the same logic is controversial in the setting of prophylactic mastectomy. METHODS: Surgeons were surveyed as to their practices. Statistical analyses were performed to identify associated factors. RESULTS: 238 surgeons responded to the survey. 73.1% of respondents stated they would always perform SLNB in the setting of mastectomy for DCIS, but only 6...
September 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28285212/glycogen-rich-clear-cell-carcinoma-grcc-of-the-breast-may-not-have-a-poor-prognosis
#10
Muna M Baslaim, Enaam M Junainah, Hadeel H Ahmad, Anmar F Semilan, Ahmed O Al-Ghamdi, Noora O Rahimuddin, Budoor A Salman
INTRODUCTION: Glycogen Rich Clear Cell Carcinoma (GRCC) is a rare variant of breast carcinomas and believed to be linked with a poor prognosis. CASE SUMMARY: We are presenting a 60-year-old Saudi lady with a 2cm GRCC carcinoma associated with clear cell ductal carcinoma in situ (DCIS) and no axillary lymph node involvement. The tumor was Estrogen and Progesterone receptors (ER & PR) positive and HER 2-neu negative. She underwent mastectomy with sentinel lymph node biopsy followed by hormonal therapy...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28173790/dcis-and-axillary-nodal-evaluation-compliance-with-national-guidelines
#11
MULTICENTER STUDY
Katrina B Mitchell, Heather Lin, Yu Shen, Alfred Colfry, Henry Kuerer, Simona F Shaitelman, Gildy V Babiera, Isabelle Bedrosian
BACKGROUND: The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) provide guidelines regarding axillary nodal evaluation in ductal carcinoma in situ (DCIS), but data regarding national compliance with these guidelines remains incomplete. METHODS: We conducted a retrospective review of the National Cancer Data Base (NCDB) analyzing all surgical approaches to axillary evaluation in patients with DCIS. Logistic regression analysis was used to assess the multivariate relationship between patient demographics, clinical characteristics, and probability of axillary evaluation...
February 7, 2017: BMC Surgery
https://www.readbyqxmd.com/read/28162949/sentinel-node-procedure-obsolete-in-lumpectomy-for-ductal-carcinoma-in-situ
#12
Cathelijne Heymans, James van Bastelaar, Ruben G J Visschers, Yvonne L J Vissers
BACKGROUND: Patients with a preoperative needle-biopsy diagnosis of ductal carcinoma in situ (DCIS) may have an indication for a sentinel lymph node biopsy if invasive carcinoma is found. We investigated how often a positive sentinel node and invasive carcinoma occurred in patients with a preoperative diagnosis of DCIS and whether this influenced the adjuvant regime. MATERIALS AND METHODS: From 2005 to 2014, the records of 240 patients with needle-biopsy diagnosis of DCIS were retrospectively reviewed for postoperative pathology outcomes of the sentinel node and breast, and decisions on adjuvant treatment...
June 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28162210/-surgical-treatment-and-prognosis-of-ductal-carcinoma-in-situ-526-cases-analysis
#13
S J Zhu, X S Chen, J Y Wu, O Huang, J R He, L Zhu, W G Chen, Y F Li, X C Fei, K W Shen
Objective: To evaluate the choice of surgical treatment of ductal carcinoma in situ (DCIS) and its impact on long-term outcomes. Methods: A retrospective analysis of the clinicopathological features and treatment protocol of DCIS patients who underwent surgical treatment in Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine from January 2009 to August 2016 was done. The factors which could affect surgical treatment were analyzed by χ(2) test and Logistic regression...
February 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/27965306/dendritic-cell-vaccination-enhances-immune-responses-and-induces-regression-of-her2-pos-dcis-independent-of-route-results-of-randomized-selection-design-trial
#14
Lea Lowenfeld, Rosemarie Mick, Jashodeep Datta, Shuwen Xu, Elizabeth Fitzpatrick, Carla S Fisher, Kevin R Fox, Angela DeMichele, Paul J Zhang, Susan P Weinstein, Robert E Roses, Brian J Czerniecki
Purpose: Vaccination with HER2 peptide-pulsed DC1s stimulates a HER2-specific T-cell response. This randomized trial aimed to establish safety and evaluate immune and clinical responses to vaccination via intralesional (IL), intranodal (IN), or both intralesional and intranodal (ILN) injection.Experimental Design: Fifty-four HER2(pos) patients [42 pure ductal carcinoma in situ (DCIS), 12 early invasive breast cancer (IBC)] were enrolled in a neoadjuvant HER2 peptide-pulsed DC1 vaccine trial. Patients were randomized to IL (n = 19), IN (n = 19), or ILN (n = 16) injection...
June 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27779988/is-sentinel-lymph-node-dissection-necessary-in-all-patients-with-ductal-carcinoma-in-situ-undergoing-total-mastectomy
#15
COMPARATIVE STUDY
Valentina Bonev, Carlos Chavez De Paz Villanueva, Naveenraj Solomon, Maheswari Senthil, Mark E Reeves, Carlos Garberoglio, Sharon S Lum
When ductal carcinoma in situ (DCIS) is found on core needle biopsy, rates of upgrade to invasive cancer of 25 per cent and nodal positivity of 10 per cent have been reported. Sentinel lymph node dissection (SLND) is recommended when mastectomy is performed for DCIS. We investigated the role of SLND in DCIS patients undergoing partial and total mastectomy (TM). During the study period 2004 to 2013, 170 patients with DCIS were identified with a median age of 60 years (range 26-84 years). Of these, 58.2 per cent had partial mastectomy (PM) alone, 10...
October 2016: American Surgeon
https://www.readbyqxmd.com/read/27773373/is-sentinel-lymph-node-biopsy-indicated-in-patients-with-a-diagnosis-of-ductal-carcinoma-in%C3%A2-situ-a-systematic-literature-review-and-meta-analysis
#16
REVIEW
Hiba El Hage Chehade, Hannah Headon, Umar Wazir, Houssam Abtar, Abdul Kasem, Kefah Mokbel
BACKGROUND: Recent discussion has suggested that some cases of ductal carcinoma in situ (DCIS) with high risk of invasive disease may require sentinel lymph node biopsy (SLNB). METHODS: Systematic literature review identified 48 studies (9,803 DCIS patients who underwent SLNB). Separate analyses for patients diagnosed preoperatively by core sampling and patients diagnosed postoperatively by specimen pathology were conducted to determine the percentage of patients with axillary nodal involvement...
January 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/27365080/axillary-evaluation-and-lymphedema-in-women-with-ductal-carcinoma-in-situ
#17
Ellie J Coromilas, Jason D Wright, Yongmei Huang, Sheldon Feldman, Alfred I Neugut, Grace Clarke Hillyer, Ling Chen, Dawn L Hershman
Axillary evaluation in women with ductal carcinoma in situ (DCIS) is increasing; however, this may introduce additional morbidity with unclear benefit. Our objective was to examine the morbidity and mortality associated with axillary evaluation in DCIS. We conducted a retrospective cohort study of 10,504 women aged 65-90 years with DCIS who underwent breast conserving surgery between 2002 and 2012 using SEER-Medicare database. Patients were categorized by receipt of axillary evaluation with either sentinel lymph node biopsy (SLNB) or axillary node dissection (ALND)...
July 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27334212/utilization-of-axillary-surgery-for-patients-with-ductal-carcinoma-in-situ-a-report-from-the-national-cancer-data-base
#18
Megan E Miller, Alexandra Kyrillos, Katharine Yao, Olga Kantor, Jennifer Tseng, David J Winchester, Lawrence N Shulman
BACKGROUND: This study evaluated the use of axillary surgery (AS), including sentinel lymph node biopsy (SLNB), for patients with ductal carcinoma in situ (DCIS) and the factors associated with its use. To determine whether utilization of SLNB is appropriate, predictors of SLNB performance were compared with factors predictive of tumor upstaging. METHODS: The National Cancer Data Base was utilized to identify patients with American Joint Committee on Cancer (AJCC) clinical stage 0 breast cancer treated from 2004 to 2013...
October 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27212695/ductal-carcinoma-in-situ-diagnosed-by-breast-needle-biopsy-predictors-of-invasion-in-the-excision-specimen
#19
S C Doebar, C de Monyé, H Stoop, J Rothbarth, S P Willemsen, C H M van Deurzen
BACKGROUND: A substantial proportion of women with a pre-operative diagnosis of pure ductal carcinoma in situ (DCIS) has a final diagnosis of invasive breast cancer (IBC) after surgical excision and, consequently, a potential indication for lymph node staging. The aim of our study was to identify novel predictors of invasion in patients with a needle-biopsy diagnosis of DCIS that would help us to select patients that may benefit from a sentinel node biopsy (SNB). PATIENTS AND METHODS: We included 153 patients with a needle-biopsy diagnosis of DCIS between 2000 and 2014, which was followed by surgical excision...
June 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27083179/sentinel-lymph-node-biopsy-can-be-omitted-in-dcis-patients-treated-with-breast-conserving-therapy
#20
L M van Roozendaal, B Goorts, M Klinkert, K B M I Keymeulen, B De Vries, L J A Strobbe, C A P Wauters, Y E van Riet, E Degreef, E J T Rutgers, J Wesseling, M L Smidt
Breast cancer guidelines advise sentinel lymph node biopsy (SLNB) in patients with ductal carcinoma in situ (DCIS) on core biopsy at high risk of invasive cancer or in case of mastectomy. This study investigates the incidence of SLNB and SLN metastases and the relevance of indications in guidelines and literature to perform SLNB in order to validate whether SLNB is justified in patients with DCIS on core biopsy in current era. Clinically node negative patients diagnosed from 2004 to 2013 with only DCIS on core needle biopsy were selected from a national database...
April 2016: Breast Cancer Research and Treatment
keyword
keyword
94209
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"